Patent · US Active

Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas

US7625915B2 · kind B2 · utility

32Cited by

112References

1Claims

0Family size

Assignee

BAYER HEALTHCARE LLC · DE

Inventors

Jacques Dumas · Neuilly-Plaisance, FR
Uday Khire · Hamden, US
Timothy B. Lowinger · Carlisle, US
Bernard Riedl · Branford, US
William Scott · Guilford, US
Roger Smith · Madison, US
Jill Wood · Hampton, US
Holia Hatoum-Mokdad · Hamden, US
Jeffrey Johnson · Branford, US
Aniko Redman · Derby, US
Robert Sibley · North Haven, US

Key dates

Filing date	Jun 26, 2007
Grant date	Dec 1, 2009
Priority date	—
Expiry date	Jun 26, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D401/12
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.